Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study

A J Swerdlow, S P Laing, Z Qiao, S D Slater, A C Burden, J L Botha, N R Waugh, A D Morris, W Gatling, E A Gale, C C Patterson, H Keen

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Raised risks of several cancers have been found in patients with type II diabetes, but there are few data on cancer risk in type I diabetes. We conducted a cohort study of 28 900 UK patients with insulin-treated diabetes followed for 520 517 person-years, and compared their cancer incidence and mortality with national expectations. To analyse by diabetes type, we examined risks separately in 23 834 patients diagnosed with diabetes under the age of 30 years, who will almost all have had type I diabetes, and 5066 patients diagnosed at ages 30 - 49 years, who probably mainly had type II. Relative risks of cancer overall were close to unity, but ovarian cancer risk was highly significantly raised in patients with diabetes diagnosed under age 30 years ( standardised incidence ratio ( SIR) = 2.14; 95% confidence interval (CI) 1.22 - 3.48; standardised mortality ratio (SMR) = 2.90; 95% CI 1.45 - 5.19), with greatest risks for those with diabetes diagnosed at ages 10 - 19 years. Risks of cancer at other major sites were not substantially raised for type I patients. The excesses of obesity- and alcohol-related cancers in type II diabetes may be due to confounding rather than diabetes per se.

Original languageEnglish
Pages (from-to)2070-2075
Number of pages6
JournalBritish Journal of Cancer
Volume92
DOIs
Publication statusPublished - 2005

Keywords

  • insulin-treated diabetes
  • cohort
  • POLYCYSTIC-OVARY-SYNDROME
  • RISK-FACTOR
  • PROSTATE-CANCER
  • MELLITUS
  • WOMEN
  • ASSOCIATION
  • ENDOMETRIAL
  • ANDROGENS
  • FREQUENCY
  • ETIOLOGY

Cite this

Swerdlow, A. J., Laing, S. P., Qiao, Z., Slater, S. D., Burden, A. C., Botha, J. L., ... Keen, H. (2005). Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. British Journal of Cancer, 92, 2070-2075. https://doi.org/10.1038/sj.bjc.6602611

Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. / Swerdlow, A J ; Laing, S P ; Qiao, Z ; Slater, S D ; Burden, A C ; Botha, J L ; Waugh, N R ; Morris, A D ; Gatling, W ; Gale, E A ; Patterson, C C ; Keen, H .

In: British Journal of Cancer, Vol. 92, 2005, p. 2070-2075.

Research output: Contribution to journalArticle

Swerdlow, AJ, Laing, SP, Qiao, Z, Slater, SD, Burden, AC, Botha, JL, Waugh, NR, Morris, AD, Gatling, W, Gale, EA, Patterson, CC & Keen, H 2005, 'Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study', British Journal of Cancer, vol. 92, pp. 2070-2075. https://doi.org/10.1038/sj.bjc.6602611
Swerdlow, A J ; Laing, S P ; Qiao, Z ; Slater, S D ; Burden, A C ; Botha, J L ; Waugh, N R ; Morris, A D ; Gatling, W ; Gale, E A ; Patterson, C C ; Keen, H . / Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. In: British Journal of Cancer. 2005 ; Vol. 92. pp. 2070-2075.
@article{441706acc915411dae1f9ae4d34d8225,
title = "Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study",
abstract = "Raised risks of several cancers have been found in patients with type II diabetes, but there are few data on cancer risk in type I diabetes. We conducted a cohort study of 28 900 UK patients with insulin-treated diabetes followed for 520 517 person-years, and compared their cancer incidence and mortality with national expectations. To analyse by diabetes type, we examined risks separately in 23 834 patients diagnosed with diabetes under the age of 30 years, who will almost all have had type I diabetes, and 5066 patients diagnosed at ages 30 - 49 years, who probably mainly had type II. Relative risks of cancer overall were close to unity, but ovarian cancer risk was highly significantly raised in patients with diabetes diagnosed under age 30 years ( standardised incidence ratio ( SIR) = 2.14; 95{\%} confidence interval (CI) 1.22 - 3.48; standardised mortality ratio (SMR) = 2.90; 95{\%} CI 1.45 - 5.19), with greatest risks for those with diabetes diagnosed at ages 10 - 19 years. Risks of cancer at other major sites were not substantially raised for type I patients. The excesses of obesity- and alcohol-related cancers in type II diabetes may be due to confounding rather than diabetes per se.",
keywords = "insulin-treated diabetes, cohort, POLYCYSTIC-OVARY-SYNDROME, RISK-FACTOR, PROSTATE-CANCER, MELLITUS, WOMEN, ASSOCIATION, ENDOMETRIAL, ANDROGENS, FREQUENCY, ETIOLOGY",
author = "Swerdlow, {A J} and Laing, {S P} and Z Qiao and Slater, {S D} and Burden, {A C} and Botha, {J L} and Waugh, {N R} and Morris, {A D} and W Gatling and Gale, {E A} and Patterson, {C C} and H Keen",
year = "2005",
doi = "10.1038/sj.bjc.6602611",
language = "English",
volume = "92",
pages = "2070--2075",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study

AU - Swerdlow, A J

AU - Laing, S P

AU - Qiao, Z

AU - Slater, S D

AU - Burden, A C

AU - Botha, J L

AU - Waugh, N R

AU - Morris, A D

AU - Gatling, W

AU - Gale, E A

AU - Patterson, C C

AU - Keen, H

PY - 2005

Y1 - 2005

N2 - Raised risks of several cancers have been found in patients with type II diabetes, but there are few data on cancer risk in type I diabetes. We conducted a cohort study of 28 900 UK patients with insulin-treated diabetes followed for 520 517 person-years, and compared their cancer incidence and mortality with national expectations. To analyse by diabetes type, we examined risks separately in 23 834 patients diagnosed with diabetes under the age of 30 years, who will almost all have had type I diabetes, and 5066 patients diagnosed at ages 30 - 49 years, who probably mainly had type II. Relative risks of cancer overall were close to unity, but ovarian cancer risk was highly significantly raised in patients with diabetes diagnosed under age 30 years ( standardised incidence ratio ( SIR) = 2.14; 95% confidence interval (CI) 1.22 - 3.48; standardised mortality ratio (SMR) = 2.90; 95% CI 1.45 - 5.19), with greatest risks for those with diabetes diagnosed at ages 10 - 19 years. Risks of cancer at other major sites were not substantially raised for type I patients. The excesses of obesity- and alcohol-related cancers in type II diabetes may be due to confounding rather than diabetes per se.

AB - Raised risks of several cancers have been found in patients with type II diabetes, but there are few data on cancer risk in type I diabetes. We conducted a cohort study of 28 900 UK patients with insulin-treated diabetes followed for 520 517 person-years, and compared their cancer incidence and mortality with national expectations. To analyse by diabetes type, we examined risks separately in 23 834 patients diagnosed with diabetes under the age of 30 years, who will almost all have had type I diabetes, and 5066 patients diagnosed at ages 30 - 49 years, who probably mainly had type II. Relative risks of cancer overall were close to unity, but ovarian cancer risk was highly significantly raised in patients with diabetes diagnosed under age 30 years ( standardised incidence ratio ( SIR) = 2.14; 95% confidence interval (CI) 1.22 - 3.48; standardised mortality ratio (SMR) = 2.90; 95% CI 1.45 - 5.19), with greatest risks for those with diabetes diagnosed at ages 10 - 19 years. Risks of cancer at other major sites were not substantially raised for type I patients. The excesses of obesity- and alcohol-related cancers in type II diabetes may be due to confounding rather than diabetes per se.

KW - insulin-treated diabetes

KW - cohort

KW - POLYCYSTIC-OVARY-SYNDROME

KW - RISK-FACTOR

KW - PROSTATE-CANCER

KW - MELLITUS

KW - WOMEN

KW - ASSOCIATION

KW - ENDOMETRIAL

KW - ANDROGENS

KW - FREQUENCY

KW - ETIOLOGY

U2 - 10.1038/sj.bjc.6602611

DO - 10.1038/sj.bjc.6602611

M3 - Article

VL - 92

SP - 2070

EP - 2075

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -